浩欧博股价跌5.11%，申万菱信基金旗下1只基金重仓，持有5.61万股浮亏损失44.75万元

Group 1 - The core point of the news is that Jiangsu Haobio Pharmaceutical Co., Ltd. experienced a decline in stock price, dropping by 5.11% to 148.07 CNY per share, with a total market capitalization of 9.399 billion CNY as of the report date [1] - The company, established on June 8, 2009, and listed on January 13, 2021, specializes in the research, production, and sales of in vitro diagnostic reagents, with 89.46% of its revenue coming from reagent sales [1] - The company's revenue composition includes 5.86% from other sales, 3.84% from instrument sales, and 0.85% from rental sales [1] Group 2 - From the perspective of fund holdings, only one fund, Shenwan Hongyuan Fund's Medical Pioneer Stock A, has a significant position in Haobio, holding 56,100 shares, which accounts for 5.74% of the fund's net value [2] - The fund has reported a loss of approximately 447,500 CNY today, with a year-to-date loss of 7% and a one-year loss of 10.41% [2] - The fund manager, Yao Hongfu, has been in charge for 3 years and 98 days, with the fund's total asset size at 133 million CNY, and the best and worst returns during his tenure being -31.23% and -32.27%, respectively [2]